Viridian Therapeutics
VRDN
165 hedge funds and large institutions have $1.98B invested in Viridian Therapeutics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 66 increasing their positions, 41 reducing their positions, and 16 closing their positions.
900% more funds holding in top 10
Funds holding in top 10: 1 → 10 (+9)
175% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 16
118% more capital invested
Capital invested by funds: $906M → $1.98B (+$1.07B)
61% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 41
20% more funds holding
Funds holding: 138 → 165 (+27)
4.75% more ownership
Funds ownership: 109.13% → 113.88% (+4.8%)
8% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $12.9M
Top Buyers
Top Sellers
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$21.4M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$11.6M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$8.38M |
| 4 |
RI
RTW Investments
New York
|
-$7.88M |
| 5 |
State Street
Boston,
Massachusetts
|
-$6.42M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AGM
176
Alpine Global Management
New York
| – | -$179K | -13,794 | Closed |
|
|
UOC
177
UBS O'Connor
Chicago,
Illinois
| – | -$131K | -10,057 | Closed |
|
|
EC
178
EntryPoint Capital
New York
| – | -$72.5K | -5,569 | Closed |
|
179
Pacer Advisors
Malvern,
Pennsylvania
| – | -$10.7K | -825 | Closed |
|
|
HT
180
Headlands Technologies
Chicago,
Illinois
| – | -$7.75K | -596 | Closed |
|
|
C
181
Covestor
London,
United Kingdom
| – | -$16 | -1 | -13% |
|
VRDN Hedge Fund Activity: Q3 2024 in Review
165 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2024, worth a combined $1.98B — up 118% from $906M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new VRDN positions and 16 closed out — a net gain of 28 holders — while 66 added to existing stakes and 41 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $32.6M. The largest seller was Maverick Capital, cutting an estimated $21.4M.
- 165 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2024, up from 138 in Q2 2024.
- Funds reported $1.98B of Viridian Therapeutics stock for Q3 2024, up 118% quarter-over-quarter.
- 44 funds opened new Viridian Therapeutics positions in Q3 2024 and 16 closed out, a net change of +28 holders.
- The largest Viridian Therapeutics buyer in Q3 2024 was Driehaus Capital Management, an estimated $32.6M added.
- The largest Viridian Therapeutics seller in Q3 2024 was Maverick Capital, an estimated $21.4M sold.
Based on aggregated 13F filings for Q3 2024.